APA   Click to copy
Sobhani, N., Generali, D., Zanconati, F., Bortul, M., & Scaggiante, B. (2018). Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World Journal of Clinical Oncology, 9(8), 172–179. https://doi.org/ 10.5306/wjco.v9.i8.172

Chicago/Turabian   Click to copy
Sobhani, Navid, Daniele Generali, Fabrizio Zanconati, Marina Bortul, and Bruna Scaggiante. “Current Status of PI3K-MTOR Inhibition in Hormone-Receptor Positive, HER2-Negative Breast Cancer.” World Journal of Clinical Oncology 9, no. 8 (2018): 172–179.

MLA   Click to copy
Sobhani, Navid, et al. “Current Status of PI3K-MTOR Inhibition in Hormone-Receptor Positive, HER2-Negative Breast Cancer.” World Journal of Clinical Oncology, vol. 9, no. 8, 2018, pp. 172–79, doi: 10.5306/wjco.v9.i8.172.

@article{navid2018a,
  title = {Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer},
  year = {2018},
  issue = {8},
  journal = {World Journal of Clinical Oncology},
  pages = {172-179},
  volume = {9},
  doi = { 10.5306/wjco.v9.i8.172},
  author = {Sobhani, Navid and Generali, Daniele and Zanconati, Fabrizio and Bortul, Marina and Scaggiante, Bruna}
}